Status:
COMPLETED
Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine Learning
Lead Sponsor:
Lizora LLC
Collaborating Sponsors:
Sheng'ai Traditional Chinese Medicine Hospital
Conditions:
COVID-19
Post-COVID-19 Syndrome
Eligibility:
All Genders
14-95 years
Brief Summary
This is an open-tabled, one-arm observatory trial to assess the effectiveness and safety of the Autonomous Treatment System Based on Machine Learning in patients with Covid-19, Post-Acute Sequelae of ...
Detailed Description
This study has enrolled 27 patients diagnosed with Covid-19, Post-Acute Sequelae of SARS-CoV-2 infection, and influenza. Of these patients, 26 are outpatients, and 1 is hospitalized. After screening b...
Eligibility Criteria
Inclusion
- Either male or female (14 years or older), and their COVID-19 vaccination status was not a factor for inclusion.
- Subjects with any high-risk conditions
- Subjects with positive sars-cov-2 rapid antigen results in 30 days
- Subjects with post Covid-19 syndrome
Exclusion
- pregnant individuals
- subjects with known histories of allergic reactions to medical herbs commonly used in Traditional Chinese Medicine (TCMs)
Key Trial Info
Start Date :
June 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT06052527
Start Date
June 16 2023
End Date
October 1 2023
Last Update
December 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheng'Ai Traditional Medicine Hospital
Kunming, Yunnan, China, 650000